What the Expanding Reach of Weight-Loss Drugs Means For Health Care 10/11/23
Listen in podcast apps:
Episode description
Shares of medical device makers like Davita and Baxter International plunged after Novo Nordisk said its GLP-1 drug Ozempic had some positive results in trials against kidney failure. So what could the impact be of a potential do-it-all drug? We surround the trade with Dr. Kavita Patel and Mizuho’s Jared Holz.